Veru will evaluate enobosarm alongside Novo Nordisk’s Wegovy in the Phase 2b PLATEAU trial in older adults with obesity.
InvestorsHub on MSN
Veru teams up with Novo Nordisk for obesity combination therapy trial (VERU)
Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming ...
Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegovy for a Phase 2b obesity trial in older adults. The PLATEAU study will test Wegovy alongside Veru’s ...
There were no increases in gastrointestinal side effects. There is also no evidence of drug-induced liver injury, or increases in obstructive sleep apnea at any dose of enobosarm compared to the ...
Veru Inc. (NASDAQ:VERU) stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction. The study evaluates the ...
Veru agreed to conduct a clinical study of one of its treatments in combination with Novo Nordisk's Wegovy weight loss drug. Under the terms of a supply agreement with Novo, Veru will conduct and ...
Stocktwits on MSN
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
Veru Inc. reported a substantial improvement in its Q2 fiscal year 2026 financial performance, marked by a significant reduction in net loss and operating expenses. The company’s stock saw a premarket ...
--International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer-- --Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR ...
Credit: Getty Images. Enobosarm is an oral, first-in-class, selective androgen receptor agonist. The Food and Drug Administration (FDA) has granted Fast Track designation to enobosarm for the ...
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with non-small cell lung cancer (NSCLC) ...
Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published i
MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (NAS: GTXI) today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition ...
MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today announced results of its two Phase 3 enobosarm clinical trials, the POWER trials, in patients with non-small cell lung cancer (NSCLC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results